Clinical trial
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
NCT00358215 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00358215 |
|---|---|
| Title | RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial |
| Official title | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure |
| Intervention type | Drug |
| Interventions | Darbepoetin alfa, Placebo |
| Enrollment | 2,278 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 11, 2012 |
| Completion | Oct 11, 2012 |
| First posted | Jul 31, 2006 |
| Last update posted | Nov 8, 2022 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, Estonia, Finland and 24 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: